License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

A phase II open label single-arm study of E7389 in patients with locally advanced or metastatic breast cancer previously treated with anthracycline taxane and capecitabine therapy refractory to the last prior therapy for their disease

To evaluate the efficacy and safety of E7389 in patients with locally advanced or metastatic breast cancer who have received anthracycline taxane and capecitabine as prior therapy and are refractory to their last chemotherapy regimen documented by progression on or within six months of therapy

FieldValue
Modified
2019-12-23
Release Date
2019-05-08
Identifier
051e1bf7-56c3-42a8-9862-b904e2574bb5
License
License Not Specified
Public Access Level
Public